Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (600332.SH) announced that its controlling subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd. ("Tianxin Pharmaceutical"), has received the "Drug Supplemental Application Approval Notice" issued by the National Medical Products Administration. The company's Ceftazidime for Injection (0.5g, 1.0g) has successfully passed the generic drug quality and efficacy consistency evaluation.

Ceftazidime for Injection is a third-generation cephalosporin antibiotic indicated for the treatment of single or multiple infections caused by susceptible microorganisms, including: systemic severe infections; lower respiratory tract infections (including pneumonia); ear, nose, and throat infections; urinary tract infections; skin and soft tissue infections; bone and joint infections; gynecological infections; gastrointestinal, biliary, and abdominal infections; hemodialysis/peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD)-related infections; central nervous system infections (including meningitis); and prevention of perioperative urinary tract infections.